LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 4 of total 4

Search options

  1. Article ; Online: Upregulation of β-catenin due to loss of miR-139 contributes to motor neuron death in amyotrophic lateral sclerosis.

    Hawkins, Sophie / Namboori, Seema C / Tariq, Ammarah / Blaker, Catherine / Flaxman, Christine / Dey, Nidhi S / Henley, Peter / Randall, Andrew / Rosa, Alessandro / Stanton, Lawrence W / Bhinge, Akshay

    Stem cell reports

    2022  Volume 17, Issue 7, Page(s) 1650–1665

    Abstract: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by the loss of motor neurons (MNs). There are no effective treatments and patients usually die within 2-5 years of diagnosis. Emerging commonalities between familial ... ...

    Abstract Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by the loss of motor neurons (MNs). There are no effective treatments and patients usually die within 2-5 years of diagnosis. Emerging commonalities between familial and sporadic cases of this complex multifactorial disorder include disruption to RNA processing and cytoplasmic inclusion bodies containing TDP-43 and/or FUS protein aggregates. Both TDP-43 and FUS have been implicated in RNA processing functions, including microRNA biogenesis, transcription, and splicing. In this study, we explore the misexpression of microRNAs in an iPSC-based disease model of FUS ALS. We identify the downregulation of miR-139, an MN-enriched microRNA, in FUS and sporadic ALS MN. We discover that miR-139 downregulation leads to the activation of canonical WNT signaling and demonstrate that the WNT transcriptional mediator β-catenin is a major driver of MN degeneration in ALS. Our results highlight the importance of homeostatic RNA networks in ALS.
    MeSH term(s) Amyotrophic Lateral Sclerosis/genetics ; Amyotrophic Lateral Sclerosis/metabolism ; DNA-Binding Proteins/metabolism ; Humans ; MicroRNAs/genetics ; MicroRNAs/metabolism ; Motor Neurons/metabolism ; Mutation ; Neurodegenerative Diseases/metabolism ; RNA-Binding Protein FUS/genetics ; RNA-Binding Protein FUS/metabolism ; Up-Regulation/genetics ; beta Catenin/genetics ; beta Catenin/metabolism
    Chemical Substances DNA-Binding Proteins ; MIRN139 microRNA, human ; MicroRNAs ; RNA-Binding Protein FUS ; beta Catenin
    Language English
    Publishing date 2022-06-23
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2720528-9
    ISSN 2213-6711 ; 2213-6711
    ISSN (online) 2213-6711
    ISSN 2213-6711
    DOI 10.1016/j.stemcr.2022.05.019
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.

    Hopcroft, Lorna / Wigmore, Eleanor M / Williamson, Stuart C / Ros, Susana / Eberlein, Cath / Moss, Jennifer I / Urosevic, Jelena / Carnevalli, Larissa S / Talbot, Sara / Bradshaw, Lauren / Blaker, Catherine / Gunda, Sreeharsha / Owenson, Venetia / Hoffmann, Scott / Sutton, Daniel / Jones, Stewart / Goodwin, Richard J A / Willis, Brandon S / Rooney, Claire /
    de Bruin, Elza C / Barry, Simon T

    NPJ breast cancer

    2023  Volume 9, Issue 1, Page(s) 64

    Abstract: Combining the selective AKT inhibitor, capivasertib, and SERD, fulvestrant improved PFS in a Phase III clinical trial (CAPItello-291), treating HR+ breast cancer patients following aromatase inhibitors, with or without CDK4/6 inhibitors. However, ... ...

    Abstract Combining the selective AKT inhibitor, capivasertib, and SERD, fulvestrant improved PFS in a Phase III clinical trial (CAPItello-291), treating HR+ breast cancer patients following aromatase inhibitors, with or without CDK4/6 inhibitors. However, clinical data suggests CDK4/6 treatment may reduce response to subsequent monotherapy endocrine treatment. To support understanding of trials such as CAPItello-291 and gain insight into this emerging population of patients, we explored how CDK4/6 inhibitor treatment influences ER+ breast tumour cell function and response to fulvestrant and capivasertib after CDK4/6 inhibitor treatment. In RB+, RB- T47D and MCF7 palbociclib-resistant cells ER pathway ER and Greb-1 expression were reduced versus naïve cells. PI3K-AKT pathway activation was also modified in RB+ cells, with capivasertib less effective at reducing pS6 in RB+ cells compared to parental cells. Expression profiling of parental versus palbociclib-resistant cells confirmed capivasertib, fulvestrant and the combination differentially impacted gene expression modulation in resistant cells, with different responses seen in T47D and MCF7 cells. Fulvestrant inhibition of ER-dependent genes was reduced. In resistant cells, the combination was less effective at reducing cell cycle genes, but a consistent reduction in cell fraction in S-phase was observed in naïve and resistant cells. Despite modified signalling responses, both RB+ and RB- resistant cells responded to combination treatment despite some reduction in relative efficacy and was effective in vivo in palbociclib-resistant PDX models. Collectively these findings demonstrate that simultaneous inhibition of AKT and ER signalling can be effective in models representing palbociclib resistance despite changes in pathway dependency.
    Language English
    Publishing date 2023-08-05
    Publishing country United States
    Document type Journal Article
    ISSN 2374-4677
    ISSN 2374-4677
    DOI 10.1038/s41523-023-00571-w
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.

    Hopcroft, Lorna / Wigmore, Eleanor M / Williamson, Stuart C / Ros, Susana / Eberlein, Cath / Moss, Jennifer I / Urosevic, Jelena / Carnevalli, Larissa S / Talbot, Sara / Bradshaw, Lauren / Blaker, Catherine / Gunda, Sreeharsha / Owenson, Venetia / Hoffmann, Scott / Sutton, Daniel / Jones, Stewart / Goodwin, Richard J A / Willis, Brandon S / Rooney, Claire /
    DeBruin, Elza / Barry, Simon T

    NPJ breast cancer

    2023  Volume 9, Issue 1, Page(s) 69

    Language English
    Publishing date 2023-08-18
    Publishing country United States
    Document type Published Erratum
    ISSN 2374-4677
    ISSN 2374-4677
    DOI 10.1038/s41523-023-00575-6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.

    Hopcroft, Lorna / Wigmore, Eleanor M / Williamson, Stuart C / Ros, Susana / Eberlein, Cath / Moss, Jennifer I / Urosevic, Jelena / Carnevalli, Larissa S / Talbot, Sara / Bradshaw, Lauren / Blaker, Catherine / Gunda, Sreeharsha / Owenson, Venetia / Hoffmann, Scott / Sutton, Daniel / Jones, Stewart / Goodwin, Richard J A / Willis, Brandon S / Rooney, Claire /
    de Bruin, Elza C / Barry, Simon T

    NPJ breast cancer

    2023  Volume 9, Issue 1, Page(s) 76

    Language English
    Publishing date 2023-09-19
    Publishing country United States
    Document type Published Erratum
    ISSN 2374-4677
    ISSN 2374-4677
    DOI 10.1038/s41523-023-00581-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top